TG Therapeutics ROE 2024

TG Therapeutics Aktienanalyse

What does TG Therapeutics do?

TG Therapeutics Inc is a biopharmaceutical company based in New York City, USA. The company was founded in 2012 and focuses on the development and commercialization of innovative therapy options for various types of cancer and autoimmune diseases. TG Therapeutics was founded as a result of a collaboration between Michael S. Weiss, an experienced investment banker and biotechnology manager, and Laurence N. Charous, an oncologist and clinical researcher. The company has roots in two predecessor companies: Manhattan Pharmaceuticals and LFB Biotechnologies. Both had failed, and TG rose from their remains. TG Therapeutics' business model is to develop a new therapy option by combining drugs of different drug classes that target the needs of patients with specific cancer conditions. The dual blockade approach, which simultaneously inhibits various signaling pathways that sustain tumor cells, is particularly promising. TG Therapeutics operates a diversified portfolio strategy and has several drug candidates in different stages of development for numerous cancer conditions, including diffuse large B-cell lymphoma, chronic lymphocytic leukemia, and multiple myeloma, as well as autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. TG Therapeutics' main products for cancer treatments currently are umapalisib and umbralisib, both of which are PI3K delta inhibitors and are being developed for the treatment of non-Hodgkin lymphomas and chronic lymphocytic leukemia. TG-1101 (Ublituximab) is a CD20-targeted antibody therapy used in lymphomas and autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. TG Therapeutics' research and development efforts are driven by an experienced team of oncologists and scientists, including CEO Michael S. Weiss. The company maintains close relationships with academic institutions and research facilities. TG Therapeutics holds a broad patent portfolio covering technologies and compounds that can be used in cancer and autoimmune disease treatment. In 2020, TG Therapeutics' revenue reached approximately $109 million, compared to $14 million in the previous year. This increase in revenue was due to the sales of umbralisib. However, the company has not yet received FDA approval for any of its drugs in the US. TG Therapeutics expects that the future success of the company will be based on the clinical activity of its pipeline, market acceptance of its products, and successful completion of studies and regulatory approvals. As of December 31, 2020, TG Therapeutics had 248 employees. The company's leading body, the board of directors, consists of an experienced team of executives and advisors, including Chairman and CEO Michael S. Weiss, CFO Sean A. Power, CMO Adam D. Feuerstein, and COO Scott T. Smith. TG Therapeutics has had a tumultuous past, but the company can now look forward to a promising pipeline and a very strong financial position. The research and development of this biopharmaceutical company are promising, and it remains to be seen which of the research products will actually break through and be introduced to the market. TG Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding TG Therapeutics's Return on Equity (ROE)

TG Therapeutics's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing TG Therapeutics's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

TG Therapeutics's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in TG Therapeutics’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about TG Therapeutics stock

What is the ROE (Return on Equity) of TG Therapeutics this year?

The ROE of TG Therapeutics this year is 0.08 undefined.

How has the Return on Equity (ROE) of TG Therapeutics developed compared to the previous year?

The ROE of TG Therapeutics has increased by -102.33% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of TG Therapeutics?

A high ROE indicates that TG Therapeutics generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of TG Therapeutics?

A low ROE can indicate that TG Therapeutics is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of TG Therapeutics affect the company?

A change in ROE (Return on Equity) of TG Therapeutics can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of TG Therapeutics?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of TG Therapeutics?

Some factors that can influence TG Therapeutics's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does TG Therapeutics pay?

Over the past 12 months, TG Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, TG Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of TG Therapeutics?

The current dividend yield of TG Therapeutics is .

When does TG Therapeutics pay dividends?

TG Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of TG Therapeutics?

TG Therapeutics paid dividends every year for the past 0 years.

What is the dividend of TG Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is TG Therapeutics located?

TG Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von TG Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of TG Therapeutics from 10/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/3/2024.

When did TG Therapeutics pay the last dividend?

The last dividend was paid out on 10/3/2024.

What was the dividend of TG Therapeutics in the year 2023?

In the year 2023, TG Therapeutics distributed 0 USD as dividends.

In which currency does TG Therapeutics pay out the dividend?

The dividends of TG Therapeutics are distributed in USD.